PBMs Suppressing Humira Biosimilars Sales, Causing Low Market Share, Report Finds

Despite the introduction of eight Humira (adalimumab) biosimilars last year, AbbVie is still holding on to its gargantuan 96 percent market share, largely because pharmacy benefit managers (PBM) are suppressing biosimilar competition, according to two new reports.
Source: Drug Industry Daily